JP2017521049A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521049A5
JP2017521049A5 JP2016567082A JP2016567082A JP2017521049A5 JP 2017521049 A5 JP2017521049 A5 JP 2017521049A5 JP 2016567082 A JP2016567082 A JP 2016567082A JP 2016567082 A JP2016567082 A JP 2016567082A JP 2017521049 A5 JP2017521049 A5 JP 2017521049A5
Authority
JP
Japan
Prior art keywords
lentiviral vector
promoter
vector according
transgene
hcef
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567082A
Other languages
English (en)
Japanese (ja)
Other versions
JP6637444B2 (ja
JP2017521049A (ja
Filing date
Publication date
Priority claimed from GB1409089.8A external-priority patent/GB2526339A/en
Application filed filed Critical
Publication of JP2017521049A publication Critical patent/JP2017521049A/ja
Publication of JP2017521049A5 publication Critical patent/JP2017521049A5/ja
Application granted granted Critical
Publication of JP6637444B2 publication Critical patent/JP6637444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567082A 2014-05-21 2015-04-23 レンチウイルスベクター Active JP6637444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1409089.8A GB2526339A (en) 2014-05-21 2014-05-21 Lentiviral vectors
GB1409089.8 2014-05-21
PCT/GB2015/051201 WO2015177501A1 (en) 2014-05-21 2015-04-23 Lentiviral vectors

Publications (3)

Publication Number Publication Date
JP2017521049A JP2017521049A (ja) 2017-08-03
JP2017521049A5 true JP2017521049A5 (enExample) 2018-06-07
JP6637444B2 JP6637444B2 (ja) 2020-01-29

Family

ID=51135270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567082A Active JP6637444B2 (ja) 2014-05-21 2015-04-23 レンチウイルスベクター

Country Status (21)

Country Link
US (1) US10704061B2 (enExample)
EP (1) EP3145949B1 (enExample)
JP (1) JP6637444B2 (enExample)
AU (1) AU2015263150B2 (enExample)
CA (1) CA2947125C (enExample)
CY (1) CY1123413T1 (enExample)
DK (1) DK3145949T3 (enExample)
EA (1) EA038966B1 (enExample)
ES (1) ES2805045T3 (enExample)
GB (1) GB2526339A (enExample)
HR (1) HRP20200930T1 (enExample)
HU (1) HUE051269T2 (enExample)
LT (1) LT3145949T (enExample)
ME (1) ME03789B (enExample)
PL (1) PL3145949T3 (enExample)
PT (1) PT3145949T (enExample)
RS (1) RS60586B1 (enExample)
SI (1) SI3145949T1 (enExample)
SM (1) SMT202000360T1 (enExample)
UA (1) UA122127C2 (enExample)
WO (1) WO2015177501A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102015012334A2 (pt) * 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
SI3377637T1 (sl) 2016-04-08 2020-08-31 Krystal Biotech, Inc. Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
JP2018174874A (ja) * 2017-04-19 2018-11-15 国立大学法人 東京医科歯科大学 上皮細胞の水分泌機能測定方法
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ, インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
GB201814590D0 (en) * 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
CN112041434A (zh) 2018-04-27 2020-12-04 克里斯托生物技术股份有限公司 用于美容性应用的编码一种或多种美容蛋白的重组核酸
CN112384247B (zh) * 2018-07-02 2024-09-27 库拉米斯公司 利用细胞融合技术的基因及细胞治疗剂以及其的用途
WO2020009444A1 (ko) * 2018-07-02 2020-01-09 서울대학교산학협력단 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
MX2021008832A (es) 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.
BR112021017853A2 (pt) * 2019-03-13 2021-11-30 Generation Bio Co Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
US20210189427A1 (en) * 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
WO2021222222A1 (en) * 2020-04-27 2021-11-04 Mccray Jr Paul B Compositions and methods for the treatment of cystic fibrosis
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
CN116157145A (zh) 2020-06-09 2023-05-23 依诺兹梅制药公司 可溶性enpp1或enpp3蛋白及其用途
KR20230074703A (ko) * 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
MX2023003021A (es) * 2020-09-16 2023-05-24 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
GB202100688D0 (en) * 2021-01-19 2021-03-03 Autolus Ltd Process
GB202102832D0 (en) * 2021-02-26 2021-04-14 Ip2Ipo Innovations Ltd Retroviral vectors
AU2022246917A1 (en) 2021-04-02 2023-10-12 Krystal Biotech, Inc. Viral vectors for cancer therapy
GB202105278D0 (en) 2021-04-13 2021-05-26 Imperial College Innovations Ltd Cell therapy
GB202105276D0 (en) * 2021-04-13 2021-05-26 Imperial College Innovations Ltd Delivery of gene therapy vectors
EP4373951A1 (en) * 2021-07-19 2024-05-29 2seventy bio, Inc. Vector manufacturing processes
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
JP2025513059A (ja) 2022-04-11 2025-04-22 アイピー2アイピーオー イノベーションズ リミテッド 組合せ治療
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
GB202212472D0 (en) * 2022-08-26 2022-10-12 Ip2Ipo Innovations Ltd Retroviral vectors
US20260053948A1 (en) 2022-09-15 2026-02-26 Yeda Research And Development Co. Ltd. Compositions and methods for virotherapy
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1980617A1 (en) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
AU2001262684A1 (en) * 2000-06-01 2001-12-11 Dnavec Research Inc. Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
WO2003029274A2 (en) 2001-09-28 2003-04-10 University Of North Carolina At Chapel Hill Paramyxoviruses as gene transfer vectors to lung cells
CA2462628C (en) * 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
DK1950307T3 (en) 2005-10-28 2016-02-15 Id Pharma Co Ltd Luftvejsepitelstamcelle for gene transfer using a lentiviral vector, which is pseudo typified by RNA virus spike protein
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
EP1950303A1 (de) 2007-01-26 2008-07-30 Bayer CropScience AG Genetisch modifizierte Pflanzen, die eine Stärke mit geringem Amylosegehalt und erhöhtem Quellvermögen synthetisieren
HUE030719T2 (en) * 2007-04-09 2017-05-29 Univ Florida Raav vector compositions having tyrosine-modified capsid proteins and methods for use

Similar Documents

Publication Publication Date Title
ME03789B (me) Lentivirusni vektori
JP7098521B2 (ja) レトロウイルス産生のための安定な細胞株
JP2018531023A5 (enExample)
CN105705645B (zh) 逆转录病毒载体
JP2024544012A5 (enExample)
DE60035589D1 (de) Viraler paramyxoviridae vektor mit einem defekten hüllprotein-gen
JP2019516410A5 (enExample)
JP2014519335A5 (enExample)
RU2014100160A (ru) Векторы генной терапии адренолейкодистрофии и адреномиелонейропатии
HK1047450A1 (zh) 含有已改变的转录起始序列的副粘病毒
JP2019500051A5 (enExample)
JP2007500017A5 (enExample)
AU2015229227A1 (en) Genomic insulator elements and uses thereof
JP6878620B2 (ja) レトロウイルス産生のための安定な細胞株
JP2014110789A (ja) ウシ免疫不全ウイルス由来ベクター
US20050148077A1 (en) Bovine immunodeficiency virus (BIV) based vectors
JP2020500562A5 (enExample)
JP2004524805A5 (enExample)
JP2025081483A5 (enExample)
JP2016530890A5 (enExample)
CN112714790A (zh) 用于生产vsv-g假型逆转录病毒载体颗粒或其病毒颗粒的ldlr阴性包装细胞系
Gashti et al. Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate
Wolkowicz et al. Lentiviral vectors for the delivery of DNA into mammalian cells
JPH11502706A (ja) シュードタイプレトロウイルス粒子
IL318838A (en) Retroviral vectors